Clinical Trials Browser

Phase 4 × ibrutinib × Clear all

NCT07474961 2026-03-16

BLOOD-dose

Phase 4 Not yet recruiting

LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT03229200 2025-10-30

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Phase 4 Active not recruiting

LymphoidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell